Navigating key news stories in pharma
Featured Stories
As chronic diseases rise globally, the bio/pharma industry is pivoting toward increasingly complex molecules that demand more sophisticated delivery strategies, which must be considered early on in development.
A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.
The companies will leverage GSK’s scientific expertise with LTZ’s immune engager platform to develop new first-in-class MCE therapies for the treatment of hematologic cancers and solid tumors.
Regeneron’s investigational gene therapy, DB-OTO, has been found to provide meaningful improvements in hearing for nearly all of the participants in the CHORD clinical trial.
Led by researchers at the University of Liverpool, a team of international scientists have discovered a new, potent class of antibiotics that will help in the fight against antimicrobial resistance.
Facing mounting cost pressures and the logistical challenges of scaling next-generation therapies, biopharma innovators are pivoting towards strategic, integrated outsourcing models, remarks Tom Sellig from Adare Pharma Solutions.
Sweden’s Nanexa has entered a licensing and option deal with Moderna, granting access to its PharmaShell drug delivery platform to develop long-acting versions of Moderna’s mRNA-based therapies.
As chronic diseases rise globally, the bio/pharma industry is pivoting toward increasingly complex molecules that demand more sophisticated delivery strategies, which must be considered early on in development.
R&D
Expansion
The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.
Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.
A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.
The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.
Dealmaking
Sweden’s Nanexa has entered a licensing and option deal with Moderna, granting access to its PharmaShell drug delivery platform to develop long-acting versions of Moderna’s mRNA-based therapies.
To strengthen its European presence and enhance high-impact event experiences for life science clients worldwide, ITA Group has acquired C2events, a UK-based event management agency specializing in healthcare and pharmaceutical conferences.
A collaboration between Rentschler Biopharma and Coriolis Pharma has been formed that will draw upon complementary scientific and technical expertise to provide end-to-end solutions for the biopharmaceutical value chain.
A strategic research collaboration has been announced by Biogen and Dayra Therapeutics aimed at the discovery and development of oral macrocyclic peptides that could disrupt traditional antibody-based treatments.
Strategy
As chronic diseases rise globally, the bio/pharma industry is pivoting toward increasingly complex molecules that demand more sophisticated delivery strategies, which must be considered early on in development.
The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.
As demand for GLP-1 obesity drugs surges and affordability remains a competitive factor in the global weight-loss market, Eli Lilly slashes tirzepatide vial prices to boost access for self-pay patients.
A fundamental, digitally driven overhaul of bio/pharmaceutical manufacturing models are needed to meet the demands of current global supply chain pressures and rising complexity of novel therapeutics.
Future Biopharma
Facing mounting cost pressures and the logistical challenges of scaling next-generation therapies, biopharma innovators are pivoting towards strategic, integrated outsourcing models, remarks Tom Sellig from Adare Pharma Solutions.
Non-invasive drug delivery via pulmonary and nasal routes is increasingly in demand; however, while there has already been significant innovation within the sector, even more is required to meet future needs.
Primary packaging requirements are evolving in line with development trends; however, flexible and easily integrated ready-to-use solutions are beneficial options, highlight Dr. Robert Lindner and Christoph Zauner from SCHOTT Pharma.
For Jacob Werlinger from Bend Bioscience, turning innovative concepts into reality requires CDMOs to not just be service providers but more of a strategic scientific partner that can help advance the concept to commercialization using the right science tools.
Regulatory
The regulator’s decision will provide a new clinical option for patients with early gastric and gastroesophageal cancers that can deliver a significant survival benefit versus chemotherapy alone.
The company’s circVec 4.0 demonstrates unprecedented gene expression levels in heart and brain tissues to open new therapeutic opportunities across multiple organs.
Having secured a European Commercial CGMP Manufacturing License from FIMEA, Nanoform is now able to produce and control the quality of nanoformed APIs for Europe and other key markets.
In light of the evolving therapeutic landscape, increasing use of advanced technologies, and political shifts, regulatory updates are inevitable, meaning that bio/pharma companies will need to adjust quickly to new requirements.
Upcoming Events
Join them for the ESACT-UK 2026 Conference that will be held on the 7th and 8th January 2026 in Oxford, UK. You can expect high-profile speakers such as Dr. Ioscani Jimenez del Val (UCD), Dr. Yusuf Johari (Lonza), Prof Gary Lye (UCL) and Prof. David James (University of Sheffield), and exciting talks across sessions.
Kick off 2026 and set the tone for the year at 18th Annual Pre-Filled Syringes and Injectable Drug Devices Conference!
This event will unite leaders and innovators from the device development industry. This highly anticipated conference offers unparalleled opportunities to explore the latest advances in combination product technology, share insights, and foster collaboration across a dynamic three-day program.
At Fierce JPM Week 2026, the sector’s most influential leaders, investors and policymakers will convene to confront these questions and chart the course ahead.